Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues

Georgia Papachristopoulou; Margaritis Avgeris; Antonios Charlaftis; Andreas Scorilas

doi:10.1160/TH10-02-0092

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(01): 131-137
DOI: 10.1160/TH10-02-0092

Cellular Proteolysis and Oncology

Schattauer GmbH

Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues

Georgia Papachristopoulou

¹Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, Greece

²Oncological Hospital “G.Gennimatas” IKA-ETAM of Athens, Athens, Greece

,

Margaritis Avgeris

¹Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, Greece

,

Antonios Charlaftis

²Oncological Hospital “G.Gennimatas” IKA-ETAM of Athens, Athens, Greece

,

Andreas Scorilas

¹Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, Greece

› Author Affiliations

Abstract

Summary

Human kallikrein-related peptidase 14 gene (KLK14) is regulated by androgens and progestins. This gene is expressed in the central nervous system and endocrine tissues such as the breast, prostate and ovary. The differential KLK14 mRNA expression levels are related to several human neoplasias, among them breast cancer. The aim of this study was to analyse the KLK14 expression in breast tissues and to investigate its differential diagnostic and prognostic value in the mammary carcinomas. For this purpose, we isolated total RNA from 70 malignant and 33 benign specimens. After testing RNA quality, we synthesised cDNA by reverse transcription and applied a highly sensitive quantitative real-time PCR (qRT-PCR) method for KLK14 mRNA quantification using the SYBR Green® chemistry. HPRT1 was used as a reference gene and the BT20 breast cancer cell line as a calibrator. Relative quantification analysis was performed using the comparative CT method 2^−ΔΔCT. KLK14 expression was detected in both types of breast tumours. However, a statistically significant increase of the KLK14 mRNA level was observed in the malignant, compared to the benign tumour samples (p<0.001), highlighting its value in discriminating these breast lesions. Elevated KLK14 expression profiles were associated with higher tumour grade (p=0.043) and size (p=0.007) in cancerous samples. Furthermore, KLK14 mRNA expression showed negative correlation in a statistically significant manner with estrogen receptor status (p=0.024). In accordance with logistic regression models (p=0.012) and receiver-operating-characteristics analysis (p<0.001), KLK14 gene expression could be evaluated as a putative independent diagnostic biomarker in breast tumour biopsies.

Keywords

KLK14 - breast cancer - biomarker - diagnosis - kallikreins

Full Text

References

References
1 Jemal A. et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2 Krishnamurthy S, Sneige N. Molecular and biologic markers of premalignant lesions of human breast. Adv Anat Pathol 2002; 09: 185-197.
3 Stark A. et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000; 18: 267-274.
4 Rohan TE. et al. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998; 90: 1262-1269.
5 Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am 2002; 29: 1-20.
6 Lundwall A. et al. A comprehensive nomenclature for serine proteases with homo-logy to tissue kallikreins. Biol Chem 2006; 387: 637-641.
7 Sotiropoulou G. et al. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009; 284: 32989-32994.
8 Diamandis EP. Prostate-specific Antigen: Its Usefulness in Clinical Medicine. Trends Endocrinol Metab 1998; 09: 310-316.
9 Black MH. et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. Br J Cancer 2000; 82: 361-367.
10 Yu H. et al. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998; 04: 1489-1497.
11 Papachristopoulou G. et al. Expression analysis and study of KLK4 in benign and malignant breast tumors. Thromb Haemost 2009; 101: 381-387.
12 Li X. et al. Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies. Cancer Sci 2009; 100: 601-607.
13 Anisowicz A. et al. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996; 02: 624-636.
14 Talieri M. et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91: 180-186.
15 Yousef GM. et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat 2003; 78: 149-158.
16 Yousef GM. et al. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 2000; 69: 331-341.
17 Chang A. et al. Human kallikrein gene 13 (KLK13) expression by quantitative RTPCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002; 86: 1457-1464.
18 Fritzsche F. et al. Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumor grades and positive nodal status. Br J Cancer 2006; 94: 540-547.
19 Yousef GM. et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer 2002; 87: 1294-1300.
20 Brattsand M. et al. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005; 124: 198-203.
21 Borgono CA. et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003; 63: 9032-9041.
22 Yousef GM. et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 2003; 119: 346-355.
23 Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361-376.
24 Avgeris M. et al. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391: 505-511.
25 Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 2010; 06: 269-285.
26 Yousef GM. et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003; 56: 287-292.
27 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
28 Thomadaki H. et al. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101: 373-380.
29 Korbakis D. et al. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clin Chem 2009; 55: 904-913.
30 Prezas P. et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 2006; 387: 807-811.
31 Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost 2009; 101: 222-224.
32 Stavropoulou P. et al. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357: 190-195.
33 Kishi T. et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003; 63: 2771-2774.
34 Kountourakis P. et al. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemost 2009; 101: 541-546.
35 Diamandis EP. et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000; 11: 54-60.
36 Soreide JA. et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 1992; 18: 112-118.
37 Vang R, Tavassoli FA. Risk for subsequent development of breast cancer. Am J Surg Pathol. 2003 27: 268–71; author reply 271–274.
38 Pike MC. et al. Estrogens, progestins, and risk of breast cancer. Ernst Schering Found Symp Proc 2007; 01: 127-150.
39 Felber LM. et al. Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem 2005; 386: 291-298.
40 Borgono CA. et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007; 282: 2405-2422.
41 Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 04: 876-890.